Metformin revisited: Does this regulator of AMP-activated protein kinase secondarily affect bone metabolism and prevent diabetic osteopathy?
| cic.isFulltext | true | es |
| cic.isPeerReviewed | true | es |
| cic.lugarDesarrollo | Universidad Nacional de La Plata | es |
| cic.version | info:eu-repo/semantics/submittedVersion | es |
| dc.date.accessioned | 2016-12-02T19:14:56Z | |
| dc.date.available | 2016-12-02T19:14:56Z | |
| dc.identifier.uri | https://digital.cic.gba.gob.ar/handle/11746/4901 | |
| dc.title | Metformin revisited: Does this regulator of AMP-activated protein kinase secondarily affect bone metabolism and prevent diabetic osteopathy? | en |
| dc.type | Artículo | es |
| dcterms.abstract | Patients with long-term type 1 and type 2 diabetes or “diabetic osteopathy”. These include osteopenia, osteoporosis and an increased incidence of low-stress fractures. In this context, it is important to evaluate whether current anti-diabetic treatments can secondarily affect bone metabolism. Adenosine monophosphateactivated protein kinase (AMPK) modulates multiple metabolic pathways and acts as a sensor of the cellular energy status; recent evidence suggests a critical role for AMPK in bone homeostasis. In addition, AMPK activation is believed to mediate most clinical effects of the insulin-sensitizer metformin. Over the past decade, several research groups have investigated the effects of metformin on bone, providing a considerable body of pre-clinical (in vitro , ex vivo and in vivo ) as well as clinical evidence for an anabolic action of metformin on bone. However, two caveats should be kept in mind when considering metformin treatment for a patient with type 2 DM at risk for diabetic osteopathy. In the first place, metformin should probably not be considered an antiosteoporotic drug; it is an insulin sensitizer with proven macrovascular benefits that can secondarily improve bone metabolism in the context of DM. Secondly, we are still awaiting the results of randomized placebo-controlled studies in humans that evaluate the effects of metformin on bone metabolism as a primary endpoint. | en |
| dcterms.creator.author | McCarthy, Antonio Desmond | es |
| dcterms.creator.author | Cortizo, Ana María | es |
| dcterms.creator.author | Sedlinsky, Claudia | es |
| dcterms.extent | 13 p. | es |
| dcterms.isPartOf.issue | vol., 7, no. 6 | es |
| dcterms.isPartOf.series | World Journal of Diabetes | es |
| dcterms.issued | 2016 | |
| dcterms.language | Español | es |
| dcterms.license | Attribution 4.0 International (BY 4.0) | es |
| dcterms.subject | Diabetes Mellitus | en |
| dcterms.subject | Osteoporosis | en |
| dcterms.subject | Bone fractures | en |
| dcterms.subject | Metformin | en |
| dcterms.subject | AMP-activated kinase | en |
| dcterms.subject.materia | Ciencias Químicas | es |
Archivos
Bloque original
1 - 1 de 1
Cargando...
- Nombre:
- 112 - McCarthy AD-World J Diabetes2016 ARTICULO.pdf-PDFA.pdf
- Tamaño:
- 961.49 KB
- Formato:
- Adobe Portable Document Format
- Descripción:
- Documento completo